Collaboration Revenue (Tables)

9 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration Revenues

The following table summarizes the amounts recorded in the consolidated statements of operations for each significant collaboration for the three and nine months ended September 30, 2014 and 2013.

	Three Months Ended September 30, 2014
	Collaboration revenue recognized from upfront and milestone payments		Collaboration revenue recognized from research and development services		Total
ZIOPHARM Oncology, Inc.	$	644	$	3,370	$	4,014
Synthetic Biologics, Inc.	163		41		204
Oragenics, Inc.	261		3		264
Fibrocell Science, Inc.	449		1,014		1,463
Genopaver, LLC	68		360		428
S & I Ophthalmic, LLC	—		667		667
OvaXon, LLC	—		813		813
Intrexon Energy Partners, LLC	625		1,535		2,160
Other	280		2,363		2,643
Total	$	2,490	$	10,166	$	12,656

	Three Months Ended September 30, 2013
	Collaboration revenue recognized from upfront and milestone payments		Collaboration revenue recognized from research and development services		Total
ZIOPHARM Oncology, Inc.	$	644	$	2,122	$	2,766
Synthetic Biologics, Inc.	163		176		339
Oragenics, Inc.	138		344		482
Fibrocell Science, Inc.	327		1,383		1,710
Genopaver, LLC	68		315		383
Other	87		261		348
Total	$	1,427	$	4,601	$	6,028

	Nine Months Ended September 30, 2014
	Collaboration revenue recognized from upfront and milestone payments		Collaboration revenue recognized from research and development services		Total
ZIOPHARM Oncology, Inc.	$	1,932	$	9,103	$	11,035
Synthetic Biologics, Inc.	488		268		756
Oragenics, Inc.	784		588		1,372
Fibrocell Science, Inc.	1,345		2,759		4,104
Genopaver, LLC	205		1,204		1,409
S & I Ophthalmic, LLC	—		2,153		2,153
OvaXon, LLC	—		1,561		1,561
Intrexon Energy Partners, LLC	1,250		2,745		3,995
Other	885		4,987		5,872
Total	$	6,889	$	25,368	$	32,257

	Nine Months Ended September 30, 2013
	Collaboration revenue recognized from upfront and milestone payments		Collaboration revenue recognized from research and development services		Total
ZIOPHARM Oncology, Inc.	$	1,932	$	5,843	$	7,775
Synthetic Biologics, Inc.	2,024		865		2,889
Oragenics, Inc.	412		1,057		1,469
Fibrocell Science, Inc.	643		2,428		3,071
Genopaver, LLC	136		528		664
Other	168		530		698
Total	$	5,315	$	11,251	$	16,566

Summary of Deferred Revenue

Deferred revenue consists of the following:

	September 30, 2014		December 31, 2013
Upfront and milestone payments	$	105,943	$	72,207
Prepaid research and development services	1,423		1,319
Prepaid product and service revenues	1,914		—
Other	572		45
Total	$	109,852	$	73,571
Current portion of deferred revenue	$	13,950	$	7,793
Long-term portion of deferred revenue	95,902		65,778
Total	$	109,852	$	73,571